| HOME >> BIOLOGY >> TECHNOLOGY |
- By June 30, 2008 Shire had agreements with nine of its top eleven
managed care organizations for VYVANSE.
- On July 2, 2008 Shire shipped to wholesalers stocks of three additional
dosage strengths (20mg, 40mg and 60mg) for VYVANSE representing product
sales of approximately $24 million. These product sales will be
recognized into revenue in Q3 2008.
LIALDA(R)/MEZAVANT - Ulcerative Colitis
- On April 1, 2008 the product was launched in Ireland as MEZAVANT XL
and, following approval in Luxembourg on June 26, 2008, is now approved
in 15 countries. Further launches are planned in certain other EU
countries during 2008, subject to the successful conclusion of pricing
and reimbursement negotiations.
- During April 2008, TAP Pharmaceutical Products Inc. ("TAP") commenced
co-promotion of LIALDA in the US in accordance with the co-promotion
agreement entered into on March 26, 2008. This agreement adds more than
500 additional sales representatives from TAP which will increase the
reach and frequency of sales calls covering an additional 22,000
doctors.
FOSRENOL - Hyperphosphatemia
- Following the launch of the product in Slovenia and Switzerland during
the second quarter of 2008 and in Malta and Malaysia in July 2008,
FOSRENOL is now available in 29 countries.
ELAPRASE(R) - Hunter syndrome
- During the three months to June 30, 2008 ELAPRASE was approved for
commercial sale in Brazil. ELAPRASE is now approved in 40 countries
worldwide.
Pipeline Highlights
INTUNIV(TM) - ADHD
- On May 8, 2008 Shire announced pivotal trial results for INTUNIV which
is in registration in the US. The data demonstrated that INTUNIV has
significant efficacy in reducing ADHD symptoms for patients taking
'/>"/>
| SOURCE Shire Ltd Copyright©2008 PR Newswire. All rights reserved |